BNP Paribas Financial Markets’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-89,500
| Closed | -$5.01M | – | 6167 |
|
|
2025
Q4 | $5.01M | Buy |
89,500
+49,500
| +124% | +$2.56M | ﹤0.01% | 2048 |
|
|
2025
Q3 | $1.92M | Hold |
40,000
| – | – | ﹤0.01% | 2632 |
|
|
2025
Q2 | $1.62M | Sell |
40,000
-1,358
| -3% | -$54.6K | ﹤0.01% | 2608 |
|
|
2025
Q1 | $1.81M | Sell |
41,358
-101,500
| -71% | -$4.48M | ﹤0.01% | 2419 |
|
|
2024
Q4 | $6.14M | Sell |
142,858
-6,561
| -4% | -$298K | ﹤0.01% | 1661 |
|
|
2024
Q3 | $6.63M | Buy |
149,419
+101,000
| +209% | +$4.32M | ﹤0.01% | 1357 |
|
|
2024
Q2 | $1.93M | Sell |
48,419
-8,809
| -15% | -$357K | ﹤0.01% | 1940 |
|
|
2024
Q1 | $2.47M | Buy |
57,228
+570
| +1% | +$24.6K | ﹤0.01% | 1928 |
|
|
2023
Q4 | $2.36M | Buy |
56,658
+51,561
| +1,012% | +$1.95M | ﹤0.01% | 1853 |
|
|
2023
Q3 | $203K | Sell |
5,097
-1,211
| -19% | -$51.2K | ﹤0.01% | 3085 |
|
|
2023
Q2 | $259K | Buy |
6,308
+903
| +17% | +$37.3K | ﹤0.01% | 2916 |
|
|
2023
Q1 | $222K | Buy |
5,405
+677
| +14% | +$28.4K | ﹤0.01% | 3109 |
|
|
2022
Q4 | $194K | Buy |
4,728
+867
| +22% | +$36.1K | ﹤0.01% | 3005 |
|
|
2022
Q3 | $155K | Buy |
3,861
+352
| +10% | +$15.1K | ﹤0.01% | 3597 |
|
|
2022
Q2 | $147K | Sell |
3,509
-866
| -20% | -$36.3K | ﹤0.01% | 3213 |
|
|
2022
Q1 | $198K | Buy |
4,375
+651
| +17% | +$28.6K | ﹤0.01% | 3136 |
|
|
2021
Q4 | $172K | Sell |
3,724
-99,979
| -96% | -$4.74M | ﹤0.01% | 3439 |
|
|
2021
Q3 | $4.92M | Buy |
103,703
+280
| +0.3% | +$13.9K | 0.01% | 1317 |
|
|
2021
Q2 | $5.35M | Buy |
103,423
+100,423
| +3,347% | +$5.04M | 0.01% | 1249 |
|
|
2021
Q1 | $151K | Hold |
3,000
| – | – | ﹤0.01% | 3166 |
|
|
2020
Q4 | $156K | Buy |
3,000
+1,000
| +50% | +$47.8K | ﹤0.01% | 2995 |
|
|
2020
Q3 | $87K | Hold |
2,000
| – | – | ﹤0.01% | 3196 |
|
|
2020
Q2 | $86K | Buy |
+2,000
| New | +$82.7K | ﹤0.01% | 2823 |
|
|
2020
Q1 | – | Sell |
-850,000
| Closed | -$38.8M | – | 4494 |
|
|
2019
Q4 | $38.8M | Buy |
+850,000
| New | +$33.7M | 0.07% | 290 |
|
|
2019
Q1 | – | Sell |
-208,000
| Closed | -$7.62M | – | 4429 |
|
|
2018
Q4 | $7.62M | Buy |
208,000
+8,000
| +4% | +$341K | 0.02% | 751 |
|
|
2018
Q3 | $9.71M | Hold |
200,000
| – | – | 0.01% | 847 |
|
|
2018
Q2 | $8.6M | Hold |
200,000
| – | – | 0.01% | 853 |
|
|
2018
Q1 | $8.37M | Buy |
+200,000
| New | +$8.72M | 0.02% | 766 |
|
|
2017
Q4 | – | Sell |
-100,000
| Closed | -$4.25M | – | 4315 |
|
|
2017
Q3 | $4.25M | Hold |
100,000
| – | – | 0.01% | 848 |
|
|
2017
Q2 | $4.3M | Hold |
100,000
| – | – | 0.01% | 831 |
|
|
2017
Q1 | $4.18M | Buy |
+100,000
| New | +$4.08M | 0.01% | 816 |
|
Other funds holding XPH
KWM
FCBT
BNP Paribas Financial Markets's XPH Position: Q1 2026 in Review
BNP Paribas Financial Markets sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2026, closing a stake of 89,500 shares — an estimated $5.01M sold.
BNP Paribas Financial Markets first reported a position in XPH in Q1 2017 and held it in 31 quarters. The position peaked at $38.8M in Q4 2019. 83 funds tracked by Wall St. Rank hold XPH as of Q1 2026.
- BNP Paribas Financial Markets reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2026 after selling out during the quarter.
- BNP Paribas Financial Markets sold 89,500 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2026, an estimated $5.01M.
- BNP Paribas Financial Markets first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2017 and held it in 31 quarters.
- BNP Paribas Financial Markets's State Street SPDR S&P Pharmaceuticals ETF position peaked at $38.8M in Q4 2019.
- 83 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.